ProQR Therapeutics (NASDAQ:PRQR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong sell rating to a hold rating in a research note released on Saturday.

PRQR has been the subject of a number of other research reports. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Weiss Ratings lowered shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. JonesTrading lowered their price target on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Finally, Chardan Capital reduced their price target on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.33.

ProQR Therapeutics Price Performance

PRQR opened at $1.93 on Friday. The business has a fifty day simple moving average of $1.75 and a 200 day simple moving average of $1.66. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10. The company has a market capitalization of $203.34 million, a PE ratio of -4.20 and a beta of 0.07.

Insiders Place Their Bets

In other news, Director Bart Filius bought 150,000 shares of the stock in a transaction on Friday, July 17th. The stock was acquired at an average price of $1.72 per share, with a total value of $258,000.00. Following the acquisition, the director directly owned 300,000 shares in the company, valued at approximately $516,000. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Boer Daniel Anton De bought 150,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was purchased at an average price of $1.74 per share, with a total value of $261,000.00. Following the completion of the transaction, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. The trade was a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 600,000 shares of company stock worth $988,500 in the last 90 days. 8.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC boosted its position in ProQR Therapeutics by 699.3% during the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 79,720 shares during the period. Bank of America Corp DE increased its position in ProQR Therapeutics by 25.7% in the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 24,347 shares during the period. BNP Paribas Financial Markets raised its stake in shares of ProQR Therapeutics by 28.4% during the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 26,893 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of ProQR Therapeutics by 86.3% during the third quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock valued at $889,000 after acquiring an additional 193,260 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.